Durability of glycemic control using U-500 insulin

Alexandria M. Dailey, Jennifer A. Gibert, Lisa R. Tannock

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Previous short-term studies evaluating U-500 insulin have reported improvements in glycemic control but with significant weight gain. This study was performed to examine the glycemic durability of U-500 insulin in highly insulin resistant subjects, and to determine if weight gain was continuous with use. Patients using U-500 insulin provided consent for chart reviews for up to 3 years prior to and 3 years after use of U-500 insulin. Charts were reviewed for physical and metabolic data from 53 subjects using U-500 insulin of which 20 used U-500 insulin for 3 years. Use of U-500 insulin led to an approximate 1% decrease in HbA1c within 3-6 months of use which was sustained for up to 3 years. Patients required increased insulin doses (by ∼80%) over the first 6-12 months with a corresponding weight gain (∼10. lbs) and a spike in hypoglycemia symptoms, but then insulin doses and body weight, as well as glycemic control and hypoglycemic symptoms, stabilized over subsequent follow up. Use of U-500 insulin in a clinical diabetes practice leads to sustained improvements in glycemic control following a period of insulin titration and weight gain. Despite the weight gain, glycemic control was sustained for up to 3 years.

Original languageEnglish (US)
Pages (from-to)340-344
Number of pages5
JournalDiabetes Research and Clinical Practice
Volume95
Issue number3
DOIs
Publication statusPublished - Mar 1 2012

    Fingerprint

Keywords

  • HbA1c
  • Hypoglycemia
  • Insulin resistance
  • Weight gain

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this